Scarica l'app Stockscreener
10.94
0.18%
0.02
Dopo l'orario di chiusura:
10.76
-0.18
-1.65%
Precedente Chiudi:
$10.92
Aprire:
$10.79
Volume 24 ore:
1.25M
Relative Volume:
1.03
Capitalizzazione di mercato:
$680.02M
Reddito:
$2.00M
Utile/perdita netta:
$-43.51M
Rapporto P/E:
-8.1551
EPS:
-1.3415
Flusso di cassa netto:
$-39.73M
1 W Prestazione:
+3.70%
1M Prestazione:
+36.92%
6M Prestazione:
+89.93%
1 anno Prestazione:
+50.90%
Intervallo 1D:
$10.53
$10.98
Intervallo di 1 settimana:
$10.15
$11.24
Portata 52W:
$4.50
$11.24
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
10.94 | 632.78M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Rodman & Renshaw | Buy |
| 2026-02-03 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-08-11 | Iniziato | Wedbush | Outperform |
| 2025-08-07 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-24 | Iniziato | Canaccord Genuity | Buy |
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan
Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - moomoo.com
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView
Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India
Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31 - moomoo.com
Balyasny Asset Management L.P. Acquires Stake in Sagimet Bioscie - GuruFocus
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - Kalkine
Sagimet Biosciences Director George Kemble Exercises Options and Sells 350,987 Shares - Kalkine Media
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat
Sagimet Biosciences (SGMT) Surges 13.7% to $10.55 as Biotech Momentum BuildsMFI Divergence - vinanet.vn
SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Spurs 13.7% Stock RallyGrowth Acceleration Report - vinanet.vn
Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen - MarketBeat
SGMT (NASDAQ: SGMT) executive plans 350,987-share stock sale under Form 144 - Stock Titan
Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp - MarketBeat
Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com South Africa
Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media
Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial - marketscreener.com
Sagimet Biosciences Inc. (SGMT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Form 8K Sagimet Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Sagimet gets FDA OK for late-stage acne trial (SGMT:NASDAQ) - Seeking Alpha
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat By Investing.com - Investing.com South Africa
Q4 EPS Estimate for Sagimet Biosciences Decreased by Analyst - MarketBeat
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat - Investing.com
FDA clears Sagimet Biosciences to begin Phase 3 trial of denifanstat for acne - Investing.com India
Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026 - TradingView
Sagimet Biosciences Announces FDA Clearance of IND for Phase 3 Denifanstat Acne Trial - Quiver Quantitative
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients - Yahoo Finance
Sagimet Biosciences director George Kemble sells $201,146 in shares By Investing.com - Investing.com Canada
Sagimet Biosciences director George Kemble sells $201,146 in shares - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Given New $56.00 Price Target at Canaccord Genuity Group - MarketBeat
Why is Sagimet Biosciences stock climbing today? By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation - simplywall.st
Why is Sagimet Biosciences stock climbing today? - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Sagimet Biosciences (SGMT) insider plans 20,206-share stock sale after option exercise - Stock Titan
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):